Ocular Therapeutix, Inc. (OCUL): Price and Financial Metrics

Ocular Therapeutix, Inc. (OCUL): $2.92

0.03 (-1.02%)

POWR Rating

Component Grades








Add OCUL to Watchlist
Sign Up

Industry: Biotech




#135 of 356

in industry

OCUL Price/Volume Stats

Current price $2.92 52-week high $7.96
Prev. close $2.95 52-week low $2.57
Day low $2.82 Volume 122,625
Day high $3.01 Avg. volume 1,157,866
50-day MA $3.85 Dividend yield N/A
200-day MA $4.78 Market Cap 231.80M

OCUL Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where OCUL ranks best; there it ranks ahead of 66.2% of US stocks.
  • OCUL's strongest trending metric is Quality; it's been moving down over the last 177 days.
  • OCUL's current lowest rank is in the Stability metric (where it is better than 11.52% of US stocks).

OCUL Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for OCUL is 17.69 -- better than 98.21% of US stocks.
  • OCUL's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 81.63% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, OCULAR THERAPEUTIX INC is reporting a growth rate of 223.17%; that's higher than 93.9% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to OCULAR THERAPEUTIX INC are ASTC, CHRS, TARS, FUV, and TTOO.
  • OCUL's SEC filings can be seen here. And to visit OCULAR THERAPEUTIX INC's official web site, go to www.ocutx.com.

OCUL Valuation Summary

  • In comparison to the median Healthcare stock, OCUL's EV/EBIT ratio is 125.86% lower, now standing at -3.
  • Over the past 112 months, OCUL's EV/EBIT ratio has gone up 10.

Below are key valuation metrics over time for OCUL.

Stock Date P/S P/B P/E EV/EBIT
OCUL 2023-09-22 4.6 82.0 -2.8 -3.0
OCUL 2023-09-21 4.7 83.8 -2.9 -3.1
OCUL 2023-09-20 4.9 87.4 -3.0 -3.2
OCUL 2023-09-19 4.9 87.4 -3.0 -3.2
OCUL 2023-09-18 4.8 85.4 -2.9 -3.1
OCUL 2023-09-15 5.1 89.5 -3.0 -3.3

OCUL Growth Metrics

    Its year over year net income to common stockholders growth rate is now at 83.04%.
  • The 4 year revenue growth rate now stands at 233.19%.
  • Its 2 year price growth rate is now at -45.39%.
Over the past 33 months, OCUL's revenue has gone up $45,499,000.

The table below shows OCUL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 49.726 -57.798 -59.346
2022-06-30 49.914 -57.611 -32.501
2022-03-31 49.366 -66.791 -22.216
2021-12-31 43.522 -65.55 -6.553
2021-09-30 38.562 -56.643 -88.315
2021-06-30 32.285 -57.319 -102.916

OCUL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OCUL has a Quality Grade of C, ranking ahead of 60.31% of graded US stocks.
  • OCUL's asset turnover comes in at 0.155 -- ranking 219th of 682 Pharmaceutical Products stocks.
  • CASI, ONVO, and DRNA are the stocks whose asset turnover ratios are most correlated with OCUL.

The table below shows OCUL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.155 0.903 -1.479
2021-03-31 0.125 0.903 -1.953
2020-12-31 0.129 0.880 -2.245
2020-09-30 0.138 0.818 -1.315
2020-06-30 0.084 0.642 -1.377
2020-03-31 0.077 0.525 -1.196

OCUL Price Target

For more insight on analysts targets of OCUL, see our OCUL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.43 Average Broker Recommendation 1.43 (Moderate Buy)

Ocular Therapeutix, Inc. (OCUL) Company Bio

Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The company was founded in 2006 and is based in Bedford, Massachusetts.

OCUL Latest News Stream

Event/Time News Detail
Loading, please wait...

OCUL Latest Social Stream

Loading social stream, please wait...

View Full OCUL Social Stream

Latest OCUL News From Around the Web

Below are the latest news stories about OCULAR THERAPEUTIX INC that investors may wish to consider to help them evaluate OCUL as an investment opportunity.

AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmologic, neurological and psychiatric disorders, today announced that the first patient has been treated in the Phase 3 registrational study in China to investigate the efficacy and safety of DEXTENZA (0.4 mg dexamethasone ophthalmic insert) in subjects following ophthalmic sur

Yahoo | September 20, 2023

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

BEDFORD, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences: H.C. Wainwright 25th Annual Global Investment ConferenceDate: Tuesday, September 12, 2023Ocular Therapeutix™ to host investor one-on-one meetingsLocation: Lotte New York Palace Hotel,

Yahoo | September 6, 2023

Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

BEDFORD, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a panel at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on Wednesday, August 16, 2023 at 11:00 AM EDT. In addition

Yahoo | August 9, 2023

Q2 2023 Ocular Therapeutix Inc Earnings Call

Q2 2023 Ocular Therapeutix Inc Earnings Call

Yahoo | August 8, 2023

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 6.90% and 3.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 7, 2023

Read More 'OCUL' Stories Here

OCUL Price Returns

1-mo -24.55%
3-mo -41.95%
6-mo -43.41%
1-year -28.52%
3-year -63.68%
5-year -55.28%
YTD 3.91%
2022 -59.68%
2021 -66.33%
2020 424.05%
2019 -0.75%
2018 -10.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!